119 related articles for article (PubMed ID: 9615761)
1. Toxicity on human hemopoietic progenitors of 2'-2'-difluoro-2'deoxycytidine (gemcitabine).
Botta M; Castello G; Ballarino P; Arboscello E; Lerza R; Mencoboni M; Pannacciulli I
Anticancer Res; 1998; 18(2A):1037-42. PubMed ID: 9615761
[TBL] [Abstract][Full Text] [Related]
2. Influence of gemcitabine (2',2'-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro.
Lech-Marańda E; Korycka A; Robak T
Eur J Haematol; 2000 Nov; 65(5):317-21. PubMed ID: 11092462
[TBL] [Abstract][Full Text] [Related]
3. In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU).
Tiefenthaler M; Hohla F; Irschick E; Strasser-Wozak E; Bacher N; Mühlmann O; Wein W; Konwalinka G
Immunobiology; 2003; 207(2):149-57. PubMed ID: 12675273
[TBL] [Abstract][Full Text] [Related]
4. The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro.
Lech-Maranda E; Korycka A; Robak T
Haematologica; 2000 Jun; 85(6):588-94. PubMed ID: 10870114
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
Bader Y; Hartmann J; Horvath Z; Saiko P; Grusch M; Madlener S; Maier S; Oehler L; Fritzer-Szekeres M; Heller N; Alken RG; Krupitza G; Szekeres T
Cancer Lett; 2008 Feb; 259(2):231-9. PubMed ID: 18023527
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells.
Cronauer MV; Klocker H; Talasz H; Geisen FH; Hobisch A; Radmayr C; Böck G; Culig Z; Schirmer M; Reissigl A; Bartsch G; Konwalinka G
Prostate; 1996 Mar; 28(3):172-81. PubMed ID: 8628720
[TBL] [Abstract][Full Text] [Related]
7. Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine).
Ruiz van Haperen VW; Veerman G; van Moorsel CJ; Peters GJ
Adv Exp Med Biol; 1998; 431():637-40. PubMed ID: 9598143
[No Abstract] [Full Text] [Related]
8. Specificity of heme for hemopoietic recovery from AZT toxicity.
Loewy G; Cook P; Ahmed T; Lutton JD; Nishimura M; Distenfeld A; Levere RD; Abraham NG
Hematol Pathol; 1992; 6(2):79-85. PubMed ID: 1607343
[TBL] [Abstract][Full Text] [Related]
9. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
Gandhi V; Mineishi S; Huang P; Yang Y; Chubb S; Chapman AJ; Nowak BJ; Hertel LW; Plunkett W
Semin Oncol; 1995 Aug; 22(4 Suppl 11):61-7. PubMed ID: 7481847
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-(1-7) synergizes with colony-stimulating factors in hematopoietic recovery.
Rodgers KE; Espinoza TB; Roda N; Meeks CJ; diZerega GS
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1235-45. PubMed ID: 24091850
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine.
Honeywell RJ; Ruiz van Haperen VW; Veerman G; Smid K; Peters GJ
Int J Biochem Cell Biol; 2015 Mar; 60():73-81. PubMed ID: 25562513
[TBL] [Abstract][Full Text] [Related]
12. Effect of deoxycytidine on 2-chloro-deoxyadenosine-mediated growth inhibition of normal human erythroid and myeloid progenitor cells.
Bilgeri R; Petzer AL; Zilian U; Geisen FH; Schirmer M; Haun M; Konwalinka G
Exp Hematol; 1993 Mar; 21(3):432-7. PubMed ID: 8095026
[TBL] [Abstract][Full Text] [Related]
13. Delayed addition of deoxycytidine protects normal CD34+ cells against cytotoxicity of gemcitabine without compromising its activity against human leukemic cells.
Tiefenthaler M; Hohla F; Strasser-Wozak E; Bacher N; Mühlmann O; Wein W; Konwalinka G
Stem Cells; 2003; 21(3):266-71. PubMed ID: 12743321
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of cladribine and gemcitabine on erythroid and granulocytic progenitors from patients with chronic myeloid leukemia.
Schirmer M; Geisen F; Tiefenthaler M; Konwalinka G
Leuk Res; 1999 Dec; 23(12):1121-6. PubMed ID: 10613357
[TBL] [Abstract][Full Text] [Related]
15. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ
Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786
[TBL] [Abstract][Full Text] [Related]
16. Effect of interleukin-1, GM-CSF, erythropoietin, and lithium on the toxicity associated with 3'-azido-3'-deoxythymidine (AZT) in vitro on hematopoietic progenitors (CFU-GM, CFU-MEG, and BFU-E) using murine retrovirus-infected hematopoietic cells.
Gallicchio VS; Hughes NK; Hulette BC; Noblitt L
J Leukoc Biol; 1991 Dec; 50(6):580-6. PubMed ID: 1940611
[TBL] [Abstract][Full Text] [Related]
17. Effects of amifostine on clonogenic mesenchymal progenitors and hematopoietic progenitors exposed to radiation.
Ramdas J; Warrier RP; Scher C; Larussa V
J Pediatr Hematol Oncol; 2003 Jan; 25(1):19-26. PubMed ID: 12544769
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
Vande Voorde J; Sabuncuoğlu S; Noppen S; Hofer A; Ranjbarian F; Fieuws S; Balzarini J; Liekens S
J Biol Chem; 2014 May; 289(19):13054-65. PubMed ID: 24668817
[TBL] [Abstract][Full Text] [Related]
19. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders.
Santini V; Bernabei A; Gozzini A; Scappini B; Zoccolante A; D'Ippolito G; Figuccia M; Ferrini PR
Haematologica; 1997; 82(1):11-5. PubMed ID: 9172997
[TBL] [Abstract][Full Text] [Related]
20. Genotoxicity kinetics in murine normoblasts as an approach for the in vivo action of difluorodeoxycytidine.
Morales-Ramírez P; Vallarino-Kelly T; Cruz-Vallejo V
Cancer Chemother Pharmacol; 2017 May; 79(5):843-853. PubMed ID: 28324147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
